Englander Institute for Precision Medicine
Found 797 results
Author Title Type [ Year(Asc)]
Filters: Corrigendum-whole-genome-and-transcriptome-analysis-pancreatic-acinar-cell-carcinoma is   [Clear All Filters]
2022
Lorenzin F, Demichelis F.  2022.  Past, Current, and Future Strategies to Target ERG Fusion-Positive Prostate Cancer.. Cancers (Basel). 14(5)
Clement CC, Osan J, Buqué A, Nanaware PP, Chang Y-C, Perino G, Shetty M, Yamazaki T, Tsai WLi, Urbanska AM et al..  2022.  PDIA3 epitope-driven immune autoreactivity contributes to hepatic damage in type 2 diabetes.. Sci Immunol. 7(74):eabl3795.
Powles T, Park SHoon, Voog E, Caserta C, Valderrama BP, Gurney H, Kalofonos H, Radulovic S, Demey W, Ullén A et al..  2022.  Plain language summary of results from the JAVELIN Bladder 100 study: avelumab maintenance treatment for advanced urothelial cancer.. Future Oncol. 18(19):2361-2371.
Álvarez-Abril B, García-Martínez E, Galluzzi L.  2022.  Platinum-based chemotherapy inflames the ovarian carcinoma microenvironment through cellular senescence.. Oncoimmunology. 11(1):2052411.
van der Heijden MS, Powles T, Petrylak D, de Wit R, Necchi A, Sternberg CN, Matsubara N, Nishiyama H, Castellano D, Hussain SA et al..  2022.  Predictive biomarkers for survival benefit with ramucirumab in urothelial cancer in the RANGE trial.. Nat Commun. 13(1):1878.
Sonpavde GP, Sternberg CN, Loriot Y, Marabelle A, Lee JLyun, Fléchon A, Roubaud G, Pouessel D, Zagonel V, Calabrò F et al..  2022.  Primary results of STRONG: An open-label, multicenter, phase 3b study of fixed-dose durvalumab monotherapy in previously treated patients with urinary tract carcinoma.. Eur J Cancer. 163:55-65.
Bellmunt J, de Wit R, Fradet Y, Climent MA, Petrylak DP, Lee J-L, Fong L, Necchi A, Sternberg CN, O'Donnell PH et al..  2022.  Putative Biomarkers of Clinical Benefit With Pembrolizumab in Advanced Urothelial Cancer: Results from the KEYNOTE-045 and KEYNOTE-052 Landmark Trials.. Clin Cancer Res. 28(10):2050-2060.
Sato A, Bloy N, Galassi C, Jiménez-Cortegana C, Klapp V, Aretz A, Guilbaud E, Yamazaki T, Petroni G, Galluzzi L et al..  2022.  Quantification of cytosolic DNA species by immunofluorescence microscopy and automated image analysis.. Methods Cell Biol. 172:115-134.
Petroni G, Cantley LC, Santambrogio L, Formenti SC, Galluzzi L.  2022.  Radiotherapy as a tool to elicit clinically actionable signalling pathways in cancer.. Nat Rev Clin Oncol. 19(2):114-131.
Sartor O, George D, Tombal B, Agarwal N, Higano CS, Sternberg CN, Miller K, Jiao XL, Guo H, Sandström P et al..  2022.  Real-world outcomes of second novel hormonal therapy or radium-223 following first novel hormonal therapy for mCRPC.. Future Oncol. 18(1):35-45.
George DJ, Agarwal N, Sartor O, Sternberg CN, Tombal B, Saad F, Miller K, Constantinovici N, Guo H, Reeves J et al..  2022.  Real-world patient characteristics associated with survival of 2 years or more after radium-223 treatment for metastatic castration-resistant prostate cancer (EPIX study).. Prostate Cancer Prostatic Dis. 25(2):306-313.
Gajic ZZ, Deshpande A, Legut M, Imielinski M, Sanjana NE.  2022.  Recurrent somatic mutations as predictors of immunotherapy response.. Nat Commun. 13(1):3938.
Han Y, Lee T, He Y, Raman R, Irizarry A, M Martin L, Giaccone G.  2022.  The regulation of CD73 in non-small cell lung cancer.. Eur J Cancer. 170:91-102.
Montrose DC, Galluzzi L.  2022.  Restored Ketosis Drives Anticancer Immunity in Colorectal Cancer.. Cancer Res. 82(8):1464-1466.
Ullmann TM, Thiesmeyer JW, Lee YJoo, Beg S, Mosquera JMiguel, Elemento O, Fahey TJ, Scognamiglio T, Houvras Y.  2022.  RET Fusion-Positive Papillary Thyroid Cancers are Associated with a More Aggressive Phenotype.. Ann Surg Oncol.
Galassi C, Ruan Y, Sato A, Jiménez-Cortegana C, Klapp V, Bloy N, Guilbaud E, Petroni G, Buqué A, Galluzzi L et al..  2022.  RT-PCR-assisted quantification of type I IFN responses in irradiated cancer cells.. Methods Cell Biol. 172:145-161.
Laurent P, Yang C, Rendeiro AF, Nilsson-Payant BE, Carrau L, Chandar V, Bram Y, tenOever BR, Elemento O, Ivashkiv LB et al..  2022.  Sensing of SARS-CoV-2 by pDCs and their subsequent production of IFN-I contribute to macrophage-induced cytokine storm during COVID-19.. Sci Immunol. 7(75):eadd4906.
Shohdy KS, Villamar DM, Cao Y, Trieu J, Price KS, Nagy R, Tagawa ST, Molina AM, Sternberg CN, Nanus DM et al..  2022.  Serial ctDNA analysis predicts clinical progression in patients with advanced urothelial carcinoma.. Br J Cancer. 126(3):430-439.
Leung W, Teater M, Durmaz C, Meydan C, Chivu AG, Chadburn A, Rice EJ, Muley A, Camarillo JM, Arivalagan J et al..  2022.  SETD2 Haploinsufficiency Enhances Germinal Center-Associated AICDA Somatic Hypermutation to Drive B-cell Lymphomagenesis.. Cancer Discov. 12(7):1782-1803.
Buyukozkan M, Suhre K, Krumsiek J.  2022.  SGI: automatic clinical subgroup identification in omics datasets.. Bioinformatics. 38(2):573-576.
Kulm S, Kofman L, Mezey J, Elemento O.  2022.  Simple Linear Cancer Risk Prediction Models With Novel Features Outperform Complex Approaches.. JCO Clin Cancer Inform. 6:e2100166.
Paulson TG, Galipeau PC, Oman KM, Sanchez CA, Kuhner MK, Smith LP, Hadi K, Shah M, Arora K, Shelton J et al..  2022.  Somatic whole genome dynamics of precancer in Barrett's esophagus reveals features associated with disease progression.. Nat Commun. 13(1):2300.
Park J, Kim J, Lewy T, Rice CM, Elemento O, Rendeiro AF, Mason CE.  2022.  Spatial omics technologies at multimodal and single cell/subcellular level.. Genome Biol. 23(1):256.
Björndahl L, Barratt CLR, Mortimer D, Agarwal A, Aitken RJ, Alvarez JG, Aneck-Hahn N, Arver S, Baldi E, Bassas L et al..  2022.  Standards in semen examination: publishing reproducible and reliable data based on high-quality methodology.. Hum Reprod. 37(11):2497-2502.
Joshua AM, Armstrong A, Crumbaker M, Scher HI, de Bono J, Tombal B, Hussain M, Sternberg CN, Gillessen S, Carles J et al..  2022.  Statin and metformin use and outcomes in patients with castration-resistant prostate cancer treated with enzalutamide: A meta-analysis of AFFIRM, PREVAIL and PROSPER.. Eur J Cancer. 170:285-295.